Full Press Release Details
HIGH POINT, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development ofcadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the H.C. Wainwright “HCW@Home” Series, being held virtually on Thursday, June 12, 2025.
Conference details are as follows:
H.C. Wainwright “HCW@Home with vTv Therapeutics”Format: Fireside ChatModerator: Emily Bodnar, Director, H.C. WainwrightvTv Therapeutics Speakers:
Date: Thursday, June 12, 2025Time: 10:00 AM ETWebcast Link: Registerhere
The webcast of the event will be accessible from News & Events page of the vTv website.
AboutvTvTherapeuticsvTv Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv's clinical pipeline is led bycadisegliatin, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules into different indications for chronic diseases. Learn more atvtvtherapeutics.comor follow the company onLinkedInorX.